Your browser doesn't support javascript.
loading
Antibody-Mediated Rejection in a Multiple Lung Transplant Patient: A Case Report.
Radeczky, P; Ghimessy, Á K; Farkas, A; Csende, K; Mészáros, L; Török, K; Fazekas, L; Agócs, L; Kocsis, Á; Bartók, T; Dancs, T; Tóth, K K; Schönauer, N; Bogyó, L; Bohács, A; Madurka, I; Elek, J; Döme, B; Rényi-Vámos, F; Lang, G; Gieszer, B.
Afiliação
  • Radeczky P; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary. Electronic address: radeczkypeter@gmail.com.
  • Ghimessy ÁK; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Farkas A; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Csende K; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary.
  • Mészáros L; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Török K; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Fazekas L; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary; The Heart and Vascular Center of Semmelweis University, Budapest, Hungary.
  • Agócs L; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Kocsis Á; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Bartók T; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Dancs T; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Tóth KK; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Schönauer N; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Bogyó L; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
  • Bohács A; Semmelweis University, Department of Pulmonology, Budapest, Hungary.
  • Madurka I; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Elek J; National Institute of Oncology, Department of Anaesthesiology and Intensive Care, Budapest, Hungary.
  • Döme B; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary; National Koranyi Institute of TB and Pulmonology, Budapest, Hungary.
  • Rényi-Vámos F; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary; Medical University of Vienna, Department of Thoracic Surgery, Wien, Austria.
  • Lang G; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary; Medical University of Vienna, Department of Thoracic Surgery, Wien, Austria.
  • Gieszer B; National Institute of Oncology, Department of Thoracic Surgery, Budapest, Hungary; Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary.
Transplant Proc ; 51(4): 1296-1298, 2019 May.
Article em En | MEDLINE | ID: mdl-31101218
Lung transplant is an effective way to treat many end-stage lung diseases. However, one of the main barriers of allograft organ transplant is still the immunologic rejection of transplanted tissue, which is a response of the HLA molecules. Rejection is a complex process involving both T-cell-mediated delayed-type hypersensitivity reactions and antibody-mediated hypersensitivity reactions to histocompatibility molecules on foreign grafts. We report the case of a 25-year-old female patient with cystic fibrosis who underwent 2 lung transplants because of her initial diagnosis and appearance of bronchiolitis obliterans syndrome after the first transplant. Only 13 months after the second transplant, despite the therapies applied, a new rejection occurred associated with high mean fluorescent intensity donor-specific antibody levels, which resulted later in the death of the patient. The present case draws attention to the importance of matching HLA molecules between donor and recipient in addition to immunosuppressive therapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reoperação / Transplante de Pulmão / Fibrose Cística / Rejeição de Enxerto Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reoperação / Transplante de Pulmão / Fibrose Cística / Rejeição de Enxerto Idioma: En Ano de publicação: 2019 Tipo de documento: Article